Advertorial

Expert View: Eshmuno® CP-FT resin – developed for the flow-through removal of aggregates using frontal chromatography

Posted: 28 June 2019 | | No comments yet

Eshmuno® CP-FT cation exchange resin is specifically designed to provide efficient removal of monoclonal antibody (mAb) aggregates in the flow-through frontal chromatography mode of operation enabling loading capacities 10-times higher than traditional bind/elute CEX chromatography. It facilitates greater manufacturing flexibility and process intensification while reducing the overall cost for the downstream purification of mAbs.

MAbs are a successful class of therapeutic proteins increasingly used in the biopharmaceutical industry, but the manufacture of safe and effective mAb drug products as well as increasing productivities of upstream processes provides many challenges to downstream purification.











To read this Expert View in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsors: Merck

The rest of this content is restricted - login or subscribe free to access

European Pharmaceutical ReviewThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 

Send this to a friend